The medication is applied to address symptom clusters that may become intense or disruptive, offering supportive therapeutic benefit. Its therapeutic focus is highly aligned with two main allergic disorders.

ЛораГЕКСАЛ is commonly used for managing symptoms associated with conditions characterized by periods of heightened symptoms, specifically Allergic Rhinitis (seasonal and perennial) and Chronic Idiopathic Urticaria (long-lasting hives). It is relevant for managing symptoms that interfere with daily comfort.

Supportive Management Across Allergic Domains

The medication is applied to address symptoms related to heightened physiological activity that are characteristic of these conditions. It supports the management of pronounced manifestations including repetitive sneezing, runny nose ( rhinorrhea), and intense itching that affects the nose, eyes, and throat. Furthermore, it is relevant for easing challenging skin symptoms like generalized pruritus and the appearance of welts or hives. This is commonly used when short-term symptomatic assistance is needed for both adults and children experiencing recurrent symptoms, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Supportive Symptom Management for Itching (Pruritus) The medication is relevant for easing symptoms that create noticeable physiological strain, commonly linked to allergic skin reactions and the nasal/ocular symptoms of hay fever.

Who can and cannot use ЛораГЕКСАЛ?

The official regulatory profile for ЛораГЕКСАЛ (Loratadine) defines eligibility based on age, physiological status, and specific medical conditions. Use is generally established for adults and adolescents (ge 12 years) and children ge 2 years old, though efficacy and safety have not been established for children under two years of age.

---

Absolute Contraindications

Use is strictly contraindicated for patients with a known hypersensitivity to Loratadine or any excipients in the formulation. It is also contraindicated in patients with rare hereditary problems, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, due to tablet components.

---

Restrictions and Limitations

Population Status	Regulatory Rule
Severe Organ Impairment	Restricted use: Patients with severe hepatic impairment or severe renal impairment require conditional use and a modified initial dose as described in the label.
Pregnancy	Not recommended or preferably avoided as a precautionary measure.
Breastfeeding	Not recommended because the active substance is excreted into breast milk.

These rules summarize the official population eligibility constraints; the medicine's use is limited to those populations where eligibility is formally established or permitted.

Interactions with other medicines and products

This section outlines information regarding interactions with other medicinal products and substances as documented in official government regulatory labels for Loratadine (the active substance in ЛораГЕКСАЛ).

Interactions with Medicinal Products

Interaction Type	Interacting Agents / Classes	Regulatory Finding and Constraint
Pharmacokinetic (PK)	Known inhibitors of CYP3A4 or CYP2D6	Co-administration may result in elevated plasma levels of Loratadine, based on the enzyme pathways involved in its metabolism.
Specific Agents Studied	Ketoconazole, Erythromycin, Cimetidine	Studies showed that the concurrent use of these specific agents led to an increase in Loratadine plasma concentrations, but without clinically significant changes (including electrocardiographic effects) in controlled trials.

Interactions with Food and Other Substances

Substance	Constraint / Finding	Official Note
Food	Slight delay in absorption timing	Concomitant ingestion of food can delay slightly the absorption of Loratadine, though this effect is not noted to influence the clinical outcome.
Alcohol	No potentiation of effects	Loratadine has no potentiating effects when administered simultaneously with alcohol, based on psychomotor performance studies.

Population Note

Interaction studies, including those with specific inhibitors, have only been performed in adults as documented in the regulatory files.

The official interaction profile for Loratadine is primarily characterized by the lack of clinically significant consequences despite observed pharmacokinetic changes (elevated plasma levels) when co-administered with known enzyme inhibitors. This regulatory documentation provides constraints on administration by noting the absence of psychomotor effects with alcohol and the minor delay in absorption when taken with food.

How ЛораГЕКСАЛ Works

Selective Inverse Agonism at the Peripheral H1-Receptor

ЛораГЕКСАЛ works by functioning as a selective inverse agonist at the peripheral H1-histamine receptor ( H1 R). The mechanism involves stabilizing the receptor in its inactive state, functionally inhibiting the molecular activation of the cascade that the endogenous mediator, histamine, normally initiates. This action directly targets the H1 R where its activity is most pronounced in the body's periphery.

---

Modulating Vascular Permeability and Nerve Stimulation

The suppression of H1 R signaling in peripheral tissues modulates the vascular system by affecting the function of capillary walls. This action reduces the histamine-driven increase in vascular permeability, which affects fluid dynamics in tissues. Furthermore, by acting peripherally and exhibiting limited ability to penetrate the blood-brain barrier (BBB), the drug results in its activity being concentrated on systems that mediate excessive nerve stimulation and localized fluid accumulation outside the Central Nervous System.

---

⏳ Sustained Pharmacodynamic Action via Active Metabolite

The pharmacodynamic effect is prolonged by the body's metabolism of the parent compound into an active derivative, Desloratadine, which continues to operate through the identical H1 R inverse agonism mechanism. This ongoing activity contributes to a prolonged suppression of the histamine signaling pathway.

How to Use ЛораГЕКСАЛ (Official Administration Guidelines)

The official administration guidelines for ЛораГЕКСАЛ (Loratadine) establish a standardized, single-dose oral regimen. The medication is delivered via the oral route as either a tablet or a liquid solution. The standard frequency for this drug is once daily, reflecting its 24-hour duration of action.

Standard Dosing: For adults and children aged 12 and older, the dose is 10 mg; children aged 6 to 11 years also receive 10 mg once daily, while children 2 to 5 years receive 5 mg once daily. The maximum recommended intake for non-adjusted patients is 10 mg per 24 hours.

The medication may be taken without regard to mealtime (with or without food) and the liquid solution requires a calibrated dosing device for accurate measurement. If a dose is missed, the next dose should be taken at the next scheduled time; patients must adhere strictly to the once-daily schedule and never double the dose.

Special Use Conditions: Specific population-based adjustments are officially mandated for patients with severe organ impairment. For those with severe hepatic or severe renal impairment (GFR < 30 mL/min), the initial dosing interval should be adjusted to 10 mg every other day for patients over 6 years of age. Furthermore, the use of Loratadine must be discontinued for at least 48 hours prior to scheduled allergy skin testing to prevent interference with diagnostic results.

Research Evidence and Overview of Studies ЛораГЕКСАЛ

This section describes the structure and scope of studies conducted with ЛораГЕКСАЛ (Loratadine), without providing clinical recommendations or interpreting results. Research provides context, but not individual predictions.

---

Evidence Base for Allergic Rhinitis (Seasonal and Perennial)

ЛораГЕКСАЛ was studied for use in conditions characterized by fluctuating or episodic manifestations, such as seasonal (hay fever) and perennial allergic rhinitis. Research includes multiple Randomized Controlled Trials (RCTs), which compared Loratadine with placebo or with other medicines. Researchers examined outcomes related to physical discomfort by monitoring manifestations such as sneezing, runny nose (rhinorrhea), and itching. Also, studies examined outcomes reflecting the level of daily activity. Patterns were recorded, associated with changes in symptoms, and studies monitored the time until initial changes were observed. Available studies provide limited information about the impact on nasal congestion compared to other symptoms.

---

Evidence Base for Chronic Idiopathic Urticaria

ЛораГЕКСАЛ was evaluated in clinical trials for managing symptoms associated with chronic idiopathic urticaria—a condition characterized by periods of heightened symptoms. Studies were conducted in the form of RCTs, comparing the results of the substance under investigation and placebo. The main focus of researchers was on outcomes related to inflammatory or irritative states, specifically changes in the intensity of itching (pruritus) and the appearance of wheals. Patterns were recorded, describing the evolution of these manifestations, in reports of short-term changes.

---

Uncertainties and Gaps in the Evidence Base

Studies contribute to the broader evidence landscape, but also point to areas where uncertainty exists. The study findings for nasal congestion were less consistent than those observed for itching or runny nose. Long-term outcomes are not well characterized, as follow-up duration was limited in most controlled studies. Comparative evidence is lacking regarding a direct comparison with all newer antihistamines. Results apply only to the populations that were studied; research provides group patterns, not personal outcomes.

Common questions about ЛораГЕКСАЛ (FAQ)

Q: Is it safe to take this drug during pregnancy or while breastfeeding?

Official regulatory information indicates that the use of this medication at recommended doses for short-term periods is typically not restricted during pregnancy and while breastfeeding. The amount of medicine that may pass into breast milk is considered low, and side effects in breastfed infants are rarely reported.

However, it is stated in official information that consultation with a healthcare professional is necessary regarding the use of any medication during these periods.

Q: Is this drug safe to use for a long time?

Regulatory documents do not include long-term use instructions for this medication. Product labels carry a warning that severe liver damage may occur if the maximum daily dose is exceeded.

Safety guidance states that if pain persists for more than 10 days or a fever lasts for more than 3 days, the user should discontinue use and consult a healthcare professional. This guidance implies the product is intended for short-term relief.

Q: Can I take this medicine with my other medications?

Official safety warnings state that this product should not be taken with other medicines containing the same active ingredient (acetaminophen), as combining them can significantly increase the risk of severe liver damage and overdose.

Official information advises consulting a healthcare provider or pharmacist for a complete review of all medications being used to check for potential interactions and ensure safe use.

Q: Can I take it for migraines?

The active substance in this medication is present in some combination drug products that are formally indicated for the treatment of migraines.

Whether the medication is appropriate for migraines is determined by the specific product formulation and its approved indications as defined in the official labeling.

Q: Can children 2 years old use it?

Yes, regulatory labeling provides specific dosing instructions for children between the ages of 2 and 12 years, typically based on weight or age.

For infants or children under 2 years of age, regulatory documents specify that consultation with a healthcare professional is required before administration of the product.

Storage and Disposal of Loratadine (ЛораГЕКСАЛ): Official Requirements

Official regulatory documents define mandatory storage and handling conditions for Loratadine products. The medicine must be stored at a temperature not exceeding 30 C or below 25 C, depending on the specific regulatory filing.

Storage and Child Safety

The product must be kept in the original package to ensure protection from light and moisture. Furthermore, as a mandatory safety requirement, this medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired product must not be thrown away via wastewater or household waste. Disposal must occur in accordance with local requirements, which often involves utilizing a pharmacy take-back program or designated pharmaceutical waste collection point.